Targeting C/EBPα overcomes primary resistance and improves the efficacy of FLT3 inhibitors in acute myeloid leukaemia

The outcomes of FLT3-ITD acute myeloid leukaemia (AML) have been improved since the approval of FLT3 inhibitors (FLT3i). However, approximately 30-50% of patients exhibit primary resistance (PR) to FLT3i with poorly defined mechanisms, posing a pressing clinical unmet need. Here, we identify C/EBPα...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Hanlin, Luo, Guanghao, Hu, Xiaobei, Xu, Gaoya, Wang, Tao, Liu, Minmin, Qiu, Xiaohui, Li, Jianan, Fu, Jingfeng, Feng, Bo, Tu, Yutong, Kan, Weijuan, Wang, Chang, Xu, Ran, Zhou, Yubo, Yang, Jianmin, Li, Jia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10076519/
https://www.ncbi.nlm.nih.gov/pubmed/37019911
http://dx.doi.org/10.1038/s41467-023-37381-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10076519/
https://www.ncbi.nlm.nih.gov/pubmed/37019911
http://dx.doi.org/10.1038/s41467-023-37381-4

Ejemplares similares